

COPD stands for chronic obstructive pulmonary disease. It is a chronic respiratory disease characterised by persistent and progressive limitation of airflow in the lungs. It most commonly develops due to long-term inhalation of harmful particles such as cigarette smoke, air pollution, occupational dust, and chemical exposure.
The main problem in COPD is that air has difficulty moving in and out of the lungs. The person especially struggles while breathing out. Over time, this may cause shortness of breath, chronic cough, sputum production, wheezing, reduced exercise capacity, and repeated exacerbations.
COPD usually progresses slowly. For this reason, many people initially attribute the symptoms to ageing, smoking, poor fitness, or weight gain. Difficulty climbing stairs, inability to walk quickly, or morning sputum may be ignored for a long time.
COPD is not diagnosed based only on symptoms. To confirm the diagnosis, a pulmonary function test called spirometry is required. After a bronchodilator medication is given, an FEV1/FVC ratio below a defined threshold indicates persistent airflow limitation.
COPD being considered advanced stage is not determined simply by saying “the patient coughs a lot” or “there is shortness of breath.” Advanced-stage assessment considers spirometry, FEV1 value, degree of breathlessness, frequency of exacerbations, history of hospitalisation, low oxygen levels, high carbon dioxide levels, exercise capacity, weight loss, muscle weakness, and accompanying heart-lung problems together.
COPD means chronic obstructive pulmonary disease.
There are three important concepts in this term.
Chronic means that the disease is long-term. COPD usually develops over years and is not considered a short-term infection that completely disappears.
Obstructive means that there is narrowing in the airways and limitation of airflow. The person cannot breathe air out of the lungs comfortably, especially during exhalation.
Pulmonary disease means that the problem may affect the bronchi, small airways, and lung tissue together.
COPD is not a single uniform condition. In some patients, chronic bronchitis features are more prominent, while in others emphysema is more dominant. In many patients, these two patterns exist together in different proportions.
Several main changes may occur in the lungs in COPD.
Chronic inflammation develops in the airways. This may cause thickening and narrowing of the bronchial walls and increased mucus production.
Narrowing and obstruction develop in the small airways. This makes it especially difficult to breathe air out of the lungs.
The air sacs in the lung tissue may become damaged. This is called emphysema. When the structure of the air sacs is disrupted, the transfer of oxygen into the blood and removal of carbon dioxide may become more difficult.
Air trapping may develop inside the lungs. The patient cannot fully empty the lungs while breathing out and begins the next breath with lungs that are already partially inflated. This may increase shortness of breath.
Over time, the respiratory muscles have to work harder. Especially in advanced stages, the person may become breathless even during simple daily activities.
Chronic bronchitis is a condition characterised by long-term cough and sputum production.
In the classic definition, cough and sputum lasting for at least three months each year for at least two consecutive years are considered meaningful for chronic bronchitis. However, in clinical assessment, not only this duration but also the patient’s overall respiratory findings and spirometry results are considered.
In chronic bronchitis, the inner lining of the bronchi becomes irritated and inflamed and produces more mucus. This may cause:
Chronic bronchitis may be part of COPD. However, not every chronic cough means COPD. Asthma, bronchiectasis, reflux, sinusitis, medication side effects, and other lung diseases may also cause chronic cough.
Emphysema is damage to the structure of the air sacs in the lungs.
Normally, air sacs help oxygen pass into the blood and carbon dioxide leave the body. In emphysema, the walls of these sacs are damaged and the elastic recoil of the lungs decreases.
As a result:
Emphysema may sometimes be clearly visible on chest CT. However, imaging alone is not enough to diagnose COPD. Airflow limitation must be shown with pulmonary function testing.
The most important cause of COPD is long-term exposure to cigarette smoke. Smoking is the best-known risk factor for COPD. However, COPD does not occur only in smokers.
Factors that may increase the risk of COPD include:
The combination of risk factors may increase the likelihood of disease development. For example, a person who smokes and is also exposed to occupational dust may have a higher risk.
Yes. COPD can also develop in people who have never smoked.
Non-smoking causes include:
For this reason, the idea “I have never smoked, so I cannot have COPD” is not correct. COPD may be considered especially in people with long-term exposure to smoke, dust, chemicals, or polluted air.
COPD symptoms may begin slowly and subtly.
The most common symptoms include:
In advanced stages, symptoms may become more obvious:
The severity of symptoms does not always match pulmonary function test results exactly. Some patients may have significant breathlessness even when FEV1 is moderately reduced. Others may have advanced test impairment but continue daily life by limiting their activity.
COPD diagnosis is based on the patient’s symptoms, risk factors, examination findings, and pulmonary function testing together.
The diagnostic process may include:
COPD is not diagnosed only with a chest X-ray. Chest X-ray may help rule out other diseases or show additional findings. However, the main test for COPD diagnosis is spirometry.
Spirometry is also known as a pulmonary function test. It is performed by asking the patient to take a deep breath and then breathe out forcefully and quickly into a device.
Spirometry assesses the amount of air entering and leaving the lungs, airflow speed, and narrowing in the airways.
The most important measurements for COPD are:
FEV1 is the amount of air a person can blow out in the first second.
FVC is the total amount of air a person can forcefully breathe out after taking a deep breath.
The FEV1/FVC ratio helps show whether there is airflow obstruction.
For COPD diagnosis, a post-bronchodilator FEV1/FVC ratio below 0.70 is the main criterion for persistent airflow limitation. However, the diagnosis should not be made by looking only at the number; symptoms and risk factors should also be considered.
A bronchodilator is an inhaled medication that temporarily widens the airways.
Spirometry may be performed before and after a bronchodilator. In COPD diagnosis, what matters is whether airflow limitation continues after the bronchodilator.
This approach helps distinguish COPD from airway diseases such as asthma, which may be more variable and reversible.
However, COPD and asthma may coexist in some patients. Therefore, test results should be evaluated together with age, symptoms, history, allergy status, smoking history, CT findings, and treatment response.
COPD staging is performed under several different headings.
The first is the degree of airflow limitation based on spirometry. This is usually expressed as GOLD 1, GOLD 2, GOLD 3, and GOLD 4.
GOLD 1 means mild airflow limitation. FEV1 may be 80% or more of the predicted value.
In this stage, some patients have few symptoms. However, cough, sputum, or shortness of breath with exertion may occur.
Calling it mild stage does not mean the disease is unimportant. Smoking cessation, avoiding risk factors, vaccination, exercise, and correct follow-up are very important during this stage.
GOLD 2 means moderate airflow limitation. FEV1 may be between 50% and 79% of the predicted value.
In this stage, shortness of breath may become more noticeable. The patient may struggle when climbing stairs, walking quickly, or carrying loads.
Many COPD patients first consult a doctor during this period because daily life starts to become limited. People enjoy convincing themselves that “my fitness has just declined” until lung capacity has already fallen; a classic human defence mechanism.
GOLD 3 means severe airflow limitation. FEV1 may be between 30% and 49% of the predicted value.
In this stage, shortness of breath affects daily life more clearly. The patient may have to slow down while walking on level ground, may struggle significantly with stairs, and may experience frequent exacerbations.
GOLD 3 is one of the important thresholds at which COPD may be considered advanced stage. However, the decision that the disease is advanced is not based only on FEV1. Symptoms, exacerbation frequency, oxygen level, and daily functional capacity are also evaluated.
GOLD 4 means very severe airflow limitation. FEV1 may be below 30% of the predicted value.
In some patients, even if FEV1 is above 30%, the disease may still be considered advanced if respiratory failure, low oxygen levels, high carbon dioxide levels, or serious clinical findings are present.
In GOLD 4:
At this stage, treatment is not only about adjusting medication. Pulmonary rehabilitation, oxygen assessment, nutrition, exacerbation prevention, advanced treatment options, and life planning should be considered together.
No. FEV1 is important in COPD assessment, but it is not sufficient on its own.
Two patients with the same FEV1 may have completely different quality of life. One patient may continue daily activities, while another may have to stop even after a short distance.
For this reason, COPD assessment uses the following information together:
COPD staging is used to guide treatment and risk assessment. However, the patient is not just a test result. Astonishing, yes, but the human body still refuses to fit neatly into an Excel sheet.
In current COPD assessment, patients are grouped not only according to FEV1 but also according to symptom burden and exacerbation risk.
This grouping is generally described as A, B, and E.
Group A includes patients with lower symptom burden and lower exacerbation risk.
In these patients, breathlessness and daily life impairment may be limited. There is usually no history of frequent exacerbations or hospitalisation in the previous year.
Group B includes patients with greater symptom burden but not necessarily very high exacerbation risk.
In these patients, shortness of breath, daily activity limitation, fatigue, and quality-of-life impairment are more noticeable. Treatment planning focuses on symptom control.
Group E refers to patients at high risk of exacerbations.
This group may include patients who have had frequent exacerbations or hospital admission in the previous year. Exacerbations may accelerate disease progression, worsen lung function, and seriously reduce quality of life.
In Group E, the goal is not only to reduce daily breathlessness. Preventing exacerbations, reducing hospital admissions, and managing long-term risk are also key aims.
COPD may be considered advanced stage in several situations.
In general, COPD may be considered advanced when:
For this reason, advanced-stage COPD does not simply mean “the breathing test is poor.” Pulmonary function, the patient’s functional capacity, and systemic effects are evaluated together.
According to spirometry, advanced COPD is usually associated with GOLD 3 and GOLD 4 levels.
In GOLD 3, FEV1 is between 30% and 49% of the predicted value. This is considered severe airflow limitation.
In GOLD 4, FEV1 is below 30% of the predicted value. This is very severe airflow limitation.
However, an FEV1 below 50% does not explain the whole picture by itself. The patient’s breathlessness, oxygen status, exacerbations, and daily life impairment must also be assessed.
In advanced COPD, shortness of breath significantly limits daily life.
The patient may:
The mMRC breathlessness scale may be used in this assessment. This scale helps understand how much breathlessness limits daily activities.
Shortness of breath is not related only to lung function. Heart disease, anaemia, muscle loss, weight, deconditioning, and anxiety may also increase breathlessness. For this reason, advanced-stage assessment should be holistic.
A COPD exacerbation is a clear worsening of respiratory symptoms beyond normal day-to-day variation.
During an exacerbation:
Frequent exacerbations in the previous year or hospitalisation due to exacerbation indicate that the disease is in a higher-risk group.
Exacerbations are important in COPD because each exacerbation may cause permanent loss of lung function, reduced quality of life, and increased hospitalisation risk.
In advanced COPD, exacerbations may be more frequent, more severe, and more difficult to recover from.
Yes. Low oxygen levels may be one of the important findings of advanced COPD.
Normally, the lungs transfer oxygen into the blood and remove carbon dioxide from the body. As COPD progresses, this gas exchange may become impaired.
Low oxygen may cause:
Oxygen saturation can be measured from the fingertip. However, the decision for long-term oxygen therapy is not made based on a single fingertip measurement. Assessment should be performed in a stable period, under appropriate conditions, and with blood gas measurement when necessary.
In advanced COPD, not only low oxygen but also high carbon dioxide levels may develop.
Carbon dioxide is a metabolic waste gas and is normally removed through breathing. When the lungs cannot ventilate adequately, carbon dioxide may accumulate in the blood.
High carbon dioxide may be associated with:
High carbon dioxide is assessed with a blood gas test. In some patients with advanced COPD, respiratory support such as non-invasive ventilation may be considered.
Long-term oxygen therapy is not given to every patient with COPD. It is evaluated only in patients who meet specific criteria for chronic low oxygen levels.
Oxygen therapy may generally be considered when:
The decision for long-term oxygen therapy is made by a physician. Oxygen equipment should not be used randomly with the logic of “I feel breathless, I will just turn it on.” Oxygen is a medication; just because it is at home does not make it a decorative object.
Yes. As COPD progresses, pressure in the blood vessels of the lungs may increase. This is called pulmonary hypertension.
Increased pressure in the lung vessels may force the right side of the heart to work harder. Over time, right heart failure may develop.
Symptoms may include:
These findings may suggest more serious systemic effects in advanced COPD. Because they may overlap with heart disease, assessment by both pulmonology and cardiology may be needed.
Yes. Advanced COPD should not be considered a disease that affects only the lungs. It may affect the whole body.
In advanced stages, some patients may experience:
The energy spent on breathing increases. At the same time, loss of appetite, inflammation, inactivity, and exacerbations may accelerate muscle loss.
As muscle strength decreases, the person moves less. As they move less, the muscles become even weaker. This creates a cycle in which breathlessness and inactivity reinforce each other.
Exercise capacity is very valuable for understanding how COPD affects daily life.
Even if test results are similar, walking distance, ability to climb stairs, and daily activity level may differ greatly between patients.
Exercise capacity may be assessed using:
In advanced COPD, the person may need to stop after a short distance. Oxygen levels may fall during exertion. This affects treatment planning.
Pulmonary rehabilitation may help reduce breathlessness, improve exercise capacity, and enhance quality of life even in advanced stages.
No. Advanced COPD and end-stage COPD should not be used as if they mean the same thing.
Advanced COPD means that the disease has features such as significant loss of lung function, severe symptoms, frequent exacerbations, or oxygen need.
End-stage COPD describes a more severe condition. At this stage, life expectancy, treatment response, frequent hospitalisation, respiratory failure, level of dependence in daily life, and need for palliative care may come into discussion.
Not every GOLD 3 patient is end-stage. Not every patient using oxygen should automatically be described as “end-stage.” These terms should be used carefully.
Symptoms may be more severe in end-stage COPD.
Possible findings include:
This picture varies from patient to patient. The term end-stage should not be based only on a test result but on clinical progression and the patient’s overall condition.
A single exacerbation does not mean that COPD has immediately progressed to advanced stage. However, frequent and severe exacerbations indicate that the disease has become higher risk.
Exacerbations are especially important when:
In such cases, treatment should be rearranged, inhaler use should be checked, vaccinations should be reviewed, and pulmonary rehabilitation and advanced treatment options should be considered.
COPD progression varies from person to person. In some people, the disease progresses slowly for years, while in others it may worsen more quickly.
Factors that may accelerate progression include:
COPD may be progressive, but the speed of progression can be modified. Smoking cessation, correct inhaler treatment, vaccinations, rehabilitation, and prevention of exacerbations may positively affect the course of the disease.
Some structural lung damage that has already occurred in COPD may not be fully reversible. However, disease progression can be slowed, symptoms can be reduced, and exacerbations can be prevented.
The most important steps include:
Progression to advanced stage may not always be completely prevented. However, with correct follow-up and treatment, quality of life can be preserved in many patients.
The aim of COPD treatment is not to “completely eliminate” the disease. The goals are to reduce symptoms, prevent exacerbations, increase daily functional capacity, and slow disease progression.
Treatment aims include:
COPD treatment should be individualised. Two patients with the same spirometry value may have different treatment needs.
Treatment of advanced COPD is planned in a multidimensional way.
Treatment areas may include:
The same treatment is not applied to every patient with advanced COPD. Treatment is determined according to disease type, emphysema distribution, exacerbation history, oxygen level, age, general health status, and the patient’s goals.
Yes. Pulmonary rehabilitation is one of the most important parts of COPD treatment. It may be useful even in advanced stages.
Pulmonary rehabilitation programmes usually include:
Pulmonary rehabilitation may not completely eliminate breathlessness. However, it may help the person move with less fear, increase muscle strength, improve exertion capacity, and remain more independent in daily life.
Inhaler medications do not completely eliminate COPD. However, by widening the airways, they may reduce breathlessness, improve exercise capacity, and reduce exacerbations.
In advanced stages, inhaler treatment is usually arranged more carefully. Long-acting bronchodilators, different medication combinations, and inhaled corticosteroids according to exacerbation risk may be considered.
For inhaler medications to work, they must be used with correct technique. An incorrectly used inhaler turns into an expensive plastic object. If the medication does not reach the lungs, treatment naturally fails to do its job.
For this reason, inhaler technique should be reviewed at follow-up visits.
No. Oxygen therapy is not given to every COPD patient with breathlessness.
Shortness of breath may sometimes increase because of air trapping, muscle weakness, deconditioning, heart disease, anaemia, or anxiety. Oxygen may be necessary only when blood oxygen levels fall below certain thresholds.
The decision for long-term oxygen therapy is based on:
In the right patient, oxygen may be important for quality of life and survival. Unnecessary or incorrect use may be ineffective, costly, and sometimes risky.
Bronchoscopic lung volume reduction treatments may be considered in selected patients with advanced emphysema. These are not suitable for every COPD patient.
In methods such as bronchoscopic valve treatment, the aim is to reduce the volume of overinflated and poorly functioning lung areas so that healthier areas can work more effectively.
Suitability assessment considers:
These treatments are evaluated in advanced centres and selected patients. Decisions are not made with the simplistic logic of “COPD is advanced, so let’s insert a valve.” Medicine does occasionally manage to be selective.
In very advanced COPD, lung transplantation may be considered in selected suitable patients. However, this is a highly specialised process.
Advanced COPD alone is not enough for lung transplantation.
Assessment includes:
Lung transplantation is not suitable for every patient with advanced COPD. Suitable patients are evaluated in detail by pulmonology and transplant centres.
In advanced COPD, the aim is not only to improve test values. It is important that the patient can maintain daily life, experience fewer exacerbations, and move more safely.
To preserve quality of life:
In advanced COPD, inactivity often makes the disease harder to manage. Obviously, the aim is not to run a marathon, but to maintain safe movement within the person’s capacity.
Some symptoms in COPD patients require urgent assessment.
Emergency care may be needed in the following situations:
In advanced COPD, exacerbations may become severe more quickly. For this reason, the patient and relatives should know the emergency warning signs.
The main specialty for COPD diagnosis and follow-up is pulmonology.
Initial assessment may be performed by a family physician or internal medicine specialist. However, pulmonology assessment is important for spirometry, treatment planning, exacerbation risk, oxygen need, and advanced treatment options.
In advanced stages, different specialties may also be involved:
COPD is a long-term disease. It is not a process that ends with a single prescription. Follow-up is at least as important as medication.
COPD is a chronic and progressive lung disease characterised by persistent airflow limitation in the airways. Although it is most commonly associated with cigarette smoke, passive smoke exposure, air pollution, occupational dust and chemical exposure, biomass smoke, and genetic causes may also play a role in COPD development.
COPD may cause shortness of breath, chronic cough, sputum production, wheezing, reduced exercise capacity, and frequent respiratory infections. Symptoms and risk factors are important, but definitive assessment is performed with spirometry.
COPD being considered advanced stage is not based on a single symptom or one test result. FEV1 falling below 50%, GOLD 3 or GOLD 4 airflow limitation, breathlessness that significantly limits daily life, frequent exacerbations, hospital admissions, low oxygen, high carbon dioxide, pulmonary hypertension, right heart failure, weight loss, and muscle wasting are important findings for advanced-stage COPD.
Advanced COPD and end-stage COPD are not the same. In advanced COPD, the disease may have reached a serious level, but treatment, rehabilitation, oxygen assessment, exacerbation prevention, and strategies to improve quality of life remain important.
One of the most critical steps in COPD treatment is smoking cessation. Correct inhaler treatment, vaccinations, pulmonary rehabilitation, physical activity, nutritional support, early management of exacerbations, and regular follow-up may also positively influence the course of the disease.
Treatment in advanced COPD should be individualised. The patient’s pulmonary function test, symptoms, exacerbation history, oxygen status, daily functional capacity, and accompanying diseases should be evaluated together.
COPD is chronic obstructive pulmonary disease. It is a chronic disease characterised by persistent airflow limitation in the lungs. Shortness of breath, cough, sputum, and reduced exercise capacity may occur.
COPD is diagnosed with symptoms, risk factors, examination, and spirometry. A post-bronchodilator FEV1/FVC ratio below 0.70 indicates persistent airflow limitation.
COPD may be considered advanced when FEV1 falls below 50%, GOLD 3 or GOLD 4 level is present, breathlessness significantly limits daily life, frequent exacerbations occur, or low oxygen levels are present.
GOLD 3 means severe airflow limitation. FEV1 is approximately between 30% and 49% of the predicted value. This level is an important indicator of advanced COPD.
GOLD 4 means very severe airflow limitation. FEV1 is below 30% of the predicted value. Respiratory failure, oxygen need, and serious daily life limitation may be seen at this stage.
No. Advanced COPD refers to a serious disease level. End-stage COPD describes a more severe condition in which life expectancy and palliative care needs may also be assessed.
Long-term oxygen therapy is considered in selected patients with persistent low oxygen levels at rest. The decision is made with fingertip oxygen measurement, blood gas analysis, and clinical assessment.
Structural lung damage that has occurred in COPD usually does not fully reverse. However, symptoms may be reduced and disease progression may be slowed with smoking cessation, correct treatment, rehabilitation, and prevention of exacerbations.
Yes. Passive smoke, air pollution, biomass smoke, occupational dust and chemicals, previous infections, and genetic causes may lead to COPD even in people who have never smoked.
A pulmonologist should be consulted for COPD diagnosis and follow-up. Initial assessment may be performed by a family physician or internal medicine specialist. In advanced stages, cardiology, rehabilitation, nutrition, thoracic surgery, or palliative care support may be needed.